23.42  1.02 (4.55%)		05-06 16:00
Open: 22.57 High: 23.51 Volume: 1,512,731		Pre. Close: 22.4 Low: 22.46 Market Cap: 2,554(M)

Short term
Mid term
Targets	6-month :	30.65	1-year :	35.81
Resists	First :	26.25	Second :	30.65
Pivot price	22.32
Supports	First :	21.89	Second :	19.2
MAs	MA(5) :	22.22	MA(20) :	22.2
	MA(100) :	17.63	MA(250) :	12.9
MACD	MACD :	0.6	Signal :	0.7
%K %D	K(14,3) :	37.6	D(3) :	30.3
RSI	RSI(14): 63.1
52-week	High :	26.25	Low :	6.03

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ DFTX ] has closed below upper band by 20.6%. Bollinger Bands are 24.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	23.54 - 23.63	23.63 - 23.72
Low:	22.23 - 22.33	22.33 - 22.44
Close:	23.24 - 23.41	23.41 - 23.58

Definium Therapeutics, Inc. is a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Tue, 24 Feb 2026
Definium Therapeutics to Participate at Upcoming Investor Conferences - Business Wire

Thu, 19 Feb 2026
Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026 - Business Wire

Wed, 21 Jan 2026
Deinium Therapeutics (DFTX) Is Up 11.5% After Psychedelic Rebrand And DT120 Roadmap Reveal Has The Bull Case Changed? - Sahm

Tue, 20 Jan 2026
Definium Therapeutics Launches Educational LSD Campaign to Advance Psychedelic Psychiatry - TipRanks

Tue, 13 Jan 2026
Mind Medicine Inc. will Change its Ticker to DFTX from MNMD - marketscreener.com

Tue, 13 Jan 2026
Mind Medicine MindMed : Definium Therapeutics Common Shares to Trade under New Nasdaq Ticker Symbol “DFTX” Effective January 15, 2026 - marketscreener.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	109 (M)
Shares Float	94 (M)
Held by Insiders	0.9 (%)
Held by Institutions	66.4 (%)
Shares Short	9,820 (K)
Shares Short P.Month	15,010 (K)

EPS	-2.06
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	3.35
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-28.1 %
Return on Equity (ttm)	-64.1 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.53
Qtrly Earnings Growth	0 %
Operating Cash Flow	-132 (M)
Levered Free Cash Flow	-58 (M)

PE Ratio	-11.37
PEG Ratio	0
Price to Book value	6.97
Price to Sales	0
Price to Cash Flow	-19.42

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.